Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients

OBJECTIVE: For most patients suffering from recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), chemotherapy is the main option after considering surgery and reirradiation. Cetuximab combined with a platinum-fluorouracil regimen (EXTREME) has been the standard of care for...

Descripción completa

Detalles Bibliográficos
Autores principales: Carinato, Hélène, Burgy, Mickaël, Ferry, Régine, Fischbach, Cathie, Kalish, Michal, Guihard, Sébastien, Brahimi, Youssef, Flesch, Henri, Bronner, Guy, Schultz, Philippe, Frasie, Véronique, Thiéry, Alicia, Demarchi, Martin, Petit, Thierry, Jung, Alain C., Wagner, Pierre, Coliat, Pierre, Borel, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580328/
https://www.ncbi.nlm.nih.gov/pubmed/34778031
http://dx.doi.org/10.3389/fonc.2021.714551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580328/
https://www.ncbi.nlm.nih.gov/pubmed/34778031
http://dx.doi.org/10.3389/fonc.2021.714551

Ejemplares similares